6-bromo-2-hydroxy-N-methyl-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carboxamide hydrochloride | 848473-77-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-bromo-2-hydroxy-N-methyl-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carboxamide hydrochloride
• 英文别名: 6-bromo-2-hydroxy-N-methyl-3-[5-(4-methylpiperazin-1-yl)sulfonylpyridin-2-yl]-1H-indole-5-carboxamide;hydrochloride
• CAS: 848473-77-8
• 化学式: C₂₀H₂₂BrN₅O₄S*ClH
• 分子量: 544.857
• InChiKey: QVEFPZXNFIYECL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.42
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  127
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  6-bromo-2-hydroxy-N-methyl-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carboxamide 在 盐酸 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 为溶剂， 生成 6-bromo-2-hydroxy-N-methyl-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carboxamide hydrochloride
  参考文献：
  名称：

  [EN] 3-HETEROCYCLYL-INDOLE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3)
  [FR] NOUVEAUX COMPOSES

  摘要：

  公开号：

  WO2005027823A3

文献信息

• 3-Heterocyclyl-Indole Derivatives as Inhibitors of Glycogen Synthase Kinase-3 (Gsk-3)
  申请人：Berg Stefan

  公开号：US20080275041A1

  公开（公告）日：2008-11-06

  Compounds of formula Ia or Ib wherein P; R 1 ; R 2 ; m; and n are as defined in the application, salts thereof, processed for their preparation, new intermediates used therein, pharmaceutical formulations containing said compounds and the use of said compounds in therapy.

  本发明涉及式Ia或Ib化合物，其中P; R1; R2; m;和n如本申请中所定义，其盐，用于其制备的加工，其中使用的新中间体，含有所述化合物的制药配方以及所述化合物在治疗中的使用。
• NEW COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1667990A2

  公开（公告）日：2006-06-14
• US7683067B2
  申请人：——

  公开号：US7683067B2

  公开（公告）日：2010-03-23
• [EN] NEW COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2005027823A2

  公开（公告）日：2005-03-31

  The present invention relates to new compounds of formula Ia or Ib wherein P represents a 5- or 6-membered heteroaromatic ring containing one or two heteroatoms selected independently from N, O and S of which at least one heteroatom is nitrogen; R1 is hydrogen; R2 is selected from: C1-6alkyl, cyano, halogen, (CO)OR10, and CONR10R11; R3 is selected from: C1-6alkyl, cyano, nitro, (CO)OR4, C1-6alkylNR4R5, OC2-6alkylNR4R5, CONR4R5, and (SO2)NR4R5; m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3 or 4; as a free base or a salt thereof, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.